TrialCancer gene therapy2009

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

J Nemunaitis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.